Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy

Insightful study that highlights how TP53 continues to be an adverse prognostic factor in DLBCL even with CAR-T therapies.

Read the full article here

Related Articles